The Hanover Insurance Group heads into the week after its Q1 earnings with a clear narrative: a solid beat has prompted a wave of analyst target upgrades, while short sellers have quietly trimmed their positions in response.
The earnings reaction was the week's defining move. The stock closed at $189.59 on Tuesday, up roughly 7% over the past month. The most recent Q1 print on April 30 sent the stock 5.3% higher the next day and held most of that gain through the week — a five-day move of nearly 5%. That pattern is consistent with prior quarters: the preceding print delivered a one-day gain of 3.9%. The next earnings event is pencilled in for July 29.
The Street responded with broad target increases. Four firms lifted their numbers in the week after results. Keefe, Bruyette & Woods raised its target to $211 while keeping an Outperform. Piper Sandler moved to $212 from $204, maintaining Overweight. Citizens lifted to $205 from $200. RBC Capital, which had cut to $190 in early April after the tariff-driven market selloff, reversed course and raised back to $195. The consensus mean price target now runs at $202 — modestly above the current price. The bull case centres on high-single-digit rate increases carrying into 2026-27, improvement in return on equity into the high teens, and strong net investment income growth. The bear case flags that loss ratios remain above pre-COVID levels and that EPS growth may decelerate over the next two years.
Short sellers are not pressing their luck. SI % FF has dropped 11.9% over the past week to 2.3% of the float — the unwind following the earnings beat is visible in the daily data, with shares short falling from around 920,000 in late April to just over 810,000. Cost to borrow is running at 0.43% — trivially cheap, down roughly 16% on the week and 22% over the past month. Borrow availability is generous, with the lending pool far from stressed. The short score of 32.7 is well below the midpoint of its range and has drifted lower all week. Nothing in the positioning data suggests a squeezable setup.
Options are also relatively subdued. The put/call ratio is at 1.74, which looks elevated in isolation but is actually below its 20-day average of 2.63 — driven down from a spike to nearly 14 in mid-April that likely reflected a specific hedging episode rather than structural bearishness. The z-score is marginally negative at -0.23, meaning options positioning is softer-than-average on a defensive read. Valuation has re-rated gently higher: the P/E is at 10.2x and the P/B at 1.63x, both up modestly over the past month. Forward EPS momentum sits in the 95th percentile, and the EPS surprise factor scores in the 84th — consistent with a company that has been outpacing expectations.
Insider activity is worth noting, though in context. Three selling transactions hit in the first two weeks of May — the HR Director sold $200k of stock, the CIO sold $184k, and the Chairman sold $641k. All were small relative to the 90-day net selling balance of roughly $6.8 million across a broad executive cluster. Most of the heavier selling occurred in a concentrated batch on February 27, when the CEO sold $2.6 million. This is a pattern more consistent with post-vesting plan sales than with a bearish signal.
Close peers AFG and AXS gained about 1.4% and 0.5% on the week respectively, while HIG and TRV slipped fractionally negative. THG's 2.7% weekly gain stands out in that context — a reflection of the post-earnings re-rating rather than sector tailwinds.
What to watch next: whether the stock can close the gap to the newly-raised analyst targets in the $205-$212 range, and whether the short selling pullback deepens or stabilises as the market digests Q1 results ahead of the July print.
See the live data behind this article on ORTEX.
Open THG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
